Light Mode
$0.3990 ↓ -0.0413 (-9.38%) Trading Down from the previous close of $0.4403, $0.0610 below the day’s high of $0.4600
-0.33 (-43.19%) / 6M
Momentum, market sentiment, and recent alerts
ONCY reads not so good: price sits below both the 20- and 200-day averages, the 12-month move is -57.7%.
Earnings, valuation, and balance sheet
Company profile and competitor comparison
Oncolytics Biotech, Inc. engages in the provision of development of immuno-oncolytic virus for the treatment of solid tumors and hematological malignancies. It offers a non-pathogenic, properietary isolation of the reovirus that induces selective tumor lysis and promotes an inflamed tumor phenotype through innate and adaptive immune responses. The company was founded by Matthew C. Coffey and Bradley George Thompson on April 2, 1998 and is headquartered in Calgary, Canada.
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.